Antiviral Therapies for Adults With Mild to Moderate COVID-19 Infection

Peggy B. Leung; Andrew M. Davis; Kristen Marks

doi:10.1001/jama.2026.6918

June 30, 2026JAMA

Antiviral Therapies for Adults With Mild to Moderate COVID-19 Infection

View at Publisher

Ask AI

Bookmark

Share

Key Points

The aim is to summarize updated recommendations for antiviral therapy in adults with mild to moderate COVID-19.
Review of the 2025 Infectious Diseases Society of America guidelines.
Focus on antiviral treatments relevant to mild to moderate COVID-19 infection.
Summary of expert recommendations for clinical practice.
Updated antiviral recommendations are provided for adults with mild to moderate COVID-19.
Key treatments are identified based on current evidence to optimize patient outcomes.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Clinical guidelines summarize updated recommendations for antiviral treatment of mild to moderate COVID-19 in adults, indicating effective care options.

Abstract

This JAMA Clinical Guidelines Synopsis summarizes the 2025 Infectious Diseases Society of America (IDSA) updated recommendations on antiviral treatment for mild to moderate COVID-19 in adults.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Leung et al. (2026) studied this question.

synapsesocial.com/papers/6a4601009ed1343031311008 https://doi.org/10.1001/jama.2026.6918

View at Publisher

Ask AI

Bookmark

Share

Antiviral Therapies for Adults With Mild to Moderate COVID-19 Infection

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Antiviral Therapies for Adults With Mild to Moderate COVID-19 Infection

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading